Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease
18 mai 2023 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, “A Phase 1b Randomized Clinical Trial of CT1812 to Measure...
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
04 mai 2023 16h05 HE
|
Cognition Therapeutics, Inc.
Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer’s disease (AD); topline results expected 2Q 2023 SHINE (AD) trial currently enrolling patients with first patient in Spain...
Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer
01 mai 2023 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), today announced the appointment of John Doyle to the role of chief financial officer. Mr. Doyle has...
Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023
19 avr. 2023 07h30 HE
|
Cognition Therapeutics, Inc.
NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting in vitro results characterizing the role of sigma-2 (σ-2) receptors and effect of CT1812...
Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases
12 avr. 2023 07h30 HE
|
Cognition Therapeutics, Inc.
NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that a review article titled, “Sigma-2 Receptors – From Basic Biology to Therapeutic Target: A...
Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes
28 mars 2023 07h30 HE
|
Cognition Therapeutics, Inc.
NEW YORK, March 28, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) presented results of a meta-analysis from the first cohort (SHINE-A) of 24 participants in the Phase 2 SHINE...
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies
27 mars 2023 08h00 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”) has released its fourth “Conversations” video podcast, a two-part...
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
23 mars 2023 07h30 HE
|
Cognition Therapeutics, Inc.
- Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease - Received FDA clearance for Phase 2 START Study of CT1812 in early Alzheimer’s disease - Received FDA...
Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023
21 mars 2023 08h00 HE
|
Cognition Therapeutics, Inc.
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples...
UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
16 mars 2023 12h18 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by...